Navigation Links
Kendle Senior Scientist Edward Sellers, MD, PhD, Named One of Nine 'Notable People in R&D'

Industry publication R&D Directions honors Dr. Sellers' pioneering work in human abuse liability studies

CINCINNATI, March 26 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced Edward Sellers, MD, PhD, Senior Scientist and General Manager of the company's Early Stage Unit in Toronto, has been named one of nine "Notable People in R&D" by leading industry publication R&D Directions. Dr. Sellers, one of only two honorees from the CRO industry to make the 2009 list, was selected based on his pioneering efforts in human abuse liability studies, assessment of abuse potential, risk mitigation, the measurement of pharmacodynamic effects of CNS drugs, pharmacogenetics and alcohol interactions.

(Logo: )

"We are pleased to have the top expert in human abuse liability assessment as part of the Kendle organization," said Simon Higginbotham, President. "With more than three decades of experience in Early Stage research, Ed is a proven leader in the Early Stage arena." He continued, "Early Stage continues to be an area of focus for Kendle, from First-in-Human studies through Phase IIa/proof-of-concept. We will continue to expand our capabilities and look forward to the ongoing contributions of Ed and our Toronto team."

Under Dr. Sellers' direction, the Kendle team in Toronto has amassed more experience in abuse liability assessments than any institution in the world and remains the only CRO conducting these studies. The unit is recognized internationally by global regulatory authorities, and has the world's largest database of recreational drug users, ensuring that subjects can be enrolled rapidly and efficiently into these critical studies. Today, the 86-bed inpatient unit is an integral part of Kendle's overall early stage services.

"I'm honored to have been chosen for this prestigious recognition," said Dr. Sellers. "I believe it is a reflection of the groundbreaking work done by my world-class team." He continued, "The abuse of prescription drugs has become a serious concern for healthcare providers, drug manufacturers and governmental regulators. Our team provides regulatory agencies and manufacturers with a scientific basis on which to schedule drugs and helps prevent the devastating effects of addiction. It is extremely rewarding to know that our team is helping the biopharmaceutical industry combat this problem."

Dr. Sellers joined Kendle in 2008 as part of the acquisition of DecisionLine Research Corporation, which he co-founded in 1997 and for which he served as President and CEO. He oversees day-to-day operations of Kendle's Early Stage Unit in Toronto as well as all scientific research conducted at the facility.

The R&D Directions editorial staff selected the 2009 "Notable People in R&D" from industry-submitted nominations based on the innovative nature of each nominee's work. The selection of Dr. Sellers marks the second time the publication has named a Kendle expert to their "Notable" list. In 2007, William Sietsema, PhD, Vice President, U.S. Regulatory Consulting and Submissions, was chosen based on his work in innovative trial design.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Kendle was recognized by FORTUNE magazine as one of the 100 fastest- growing companies in the United States for 2008. The company also has been recognized as the "Top CRO to Work With" in the CenterWatch 2007 survey of U.S. investigative sites and among the "Top CROs in Europe" in the 2008 survey of European sites.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the Company's Web site at

SOURCE Kendle International Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle to Ring Opening Bell at NASDAQ Stock Market on August 22
2. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
3. Kendle to Present at Thomas Weisel Partners Healthcare Conference 2007
4. Kendle to Present at Bear Stearns 20th Annual Healthcare Conference
5. Kendle to Present at the UBS Global Life Sciences Conference
6. Kendle to Present at the Natixis Bleichroeder Hidden Gems Conference
7. Kendle Invites You to Attend Its Third Quarter 2007 Earnings Conference Call and Webcast
8. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
9. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
10. Kendle to Present at the Wachovia 2008 Healthcare Conference
11. Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality
Post Your Comments:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... bring innovative medical technologies, services and solutions to the healthcare market. The company's ... of various distribution, manufacturing, sales and marketing strategies that are necessary to help ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
Breaking Biology Technology:
(Date:6/22/2016)...  The American College of Medical Genetics and Genomics was ... as one of the fastest-growing trade shows during the Fastest ... in Las Vegas . ... in each of the following categories: net square feet of ... attendees. The 2015 ACMG Annual Meeting was ranked 23 out ...
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/3/2016)... Das DOTM (Department ... hat ein 44 Millionen $-Projekt ... einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an Decatur ... Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale Anbieter ... aber Decatur wurde als konformste und innovativste ...
Breaking Biology News(10 mins):